NCT00577122 2023-10-16
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Indiana University
Phase 2 Completed
Indiana University
University of California, San Diego
Dana-Farber Cancer Institute
University of California, San Francisco
University of Oxford
University of Washington
University of Washington
University of Washington
Memorial Sloan Kettering Cancer Center
ETOP IBCSG Partners Foundation
Dana-Farber Cancer Institute